Literature DB >> 28870578

Depression and fatigue in patients with multiple sclerosis.

Emily E Greeke1, Alicia S Chua1, Brian C Healy2, David J Rintell3, Tanuja Chitnis4, Bonnie I Glanz5.   

Abstract

BACKGROUND: Previous research has examined the components of depression and fatigue in multiple sclerosis (MS), but the findings have been inconsistent. The aim of this study was to explore the associations between overall and subscale scores of the Center for Epidemiologic Studies-Depression Scale (CES-D) and the Modified Fatigue Impact Scale (MFIS) as well as the longitudinal changes in scores in a large cohort of MS patients.
METHODS: MS subjects who completed a battery of patient reported outcome (PRO) measures including the CES-D and MFIS (N=435) were included in our analysis. At the first available MFIS measurement, Pearson's correlation coefficient was used to estimate the association between the CES-D and MFIS in terms of both total scores and subscale scores. In addition, the longitudinal change in each total score and subscale score was estimated using a linear mixed model, and the association between the measures in terms of longitudinal change was estimated using Pearson's correlation coefficient and linear mixed models.
RESULTS: At baseline, 15% of subjects were classified as high on both depression and fatigue scales, 16% were classified as high on the fatigue scale only, and 9% were classified as high on the depression scale only. There was a high correlation between CES-D and MFIS total scores (r=0.62). High correlations were also observed between the somatic and retarded activity subscales of the CES-D and each of the MFIS subscales (r≥0.60). In terms of longitudinal change, the change over the first year between the CES-D and MFIS total scores showed a moderate correlation (r=0.49). Subjects with high fatigue scores but low depression scores at baseline were more likely than subjects with low baseline fatigue and depression scores to develop high depression scores at follow-up.
CONCLUSIONS: Our study demonstrated that depression and fatigue in MS share several features and have a similar longitudinal course. But using cut-off scores to define depression and fatigue, our study also found that non-depressed subjects with high fatigue may be at a greater risk for developing depression.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Depression; Fatigue; Multiple sclerosis; Patient reported outcomes; Quality of life

Mesh:

Year:  2017        PMID: 28870578     DOI: 10.1016/j.jns.2017.07.047

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  10 in total

1.  Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS).

Authors:  Ilaria Ruotolo; Giovanni Sellitto; Antonio Ianniello; Nikolaos Petsas; Letizia Castelli; Giovanni Galeoto; Anna Berardi; Valeria Barletta; Antonella Conte; Carlo Pozzilli
Journal:  Neurol Sci       Date:  2022-04-22       Impact factor: 3.830

2.  Barriers to quality of life in patients with multiple sclerosis: a qualitative study.

Authors:  Zahra Hosseini; Atefeh Homayuni; Masoud Etemadifar
Journal:  BMC Neurol       Date:  2022-05-13       Impact factor: 2.903

Review 3.  Depressive Syndromes in Autoimmune Disorders of the Nervous System: Prevalence, Etiology, and Influence.

Authors:  Yanjun Liu; Xiangqi Tang
Journal:  Front Psychiatry       Date:  2018-09-25       Impact factor: 4.157

4.  Cognitive Functioning in Patients with Pediatric-Onset Multiple Sclerosis, an Updated Review and Future Focus.

Authors:  Joy B Parrish; Emily Fields
Journal:  Children (Basel)       Date:  2019-02-04

5.  Microglial Phagocytosis of Neurons: Diminishing Neuronal Loss in Traumatic, Infectious, Inflammatory, and Autoimmune CNS Disorders.

Authors:  Samuel F Yanuck
Journal:  Front Psychiatry       Date:  2019-10-03       Impact factor: 4.157

6.  The Complex Interplay Between Trait Fatigue and Cognition in Multiple Sclerosis.

Authors:  C Guillemin; E Lommers; G Delrue; E Gester; P Maquet; F Collette
Journal:  Psychol Belg       Date:  2022-03-16

7.  Treatment choices and neuropsychological symptoms of a large cohort of early MS.

Authors:  Olga von Bismarck; Theresa Dankowski; Björn Ambrosius; Nicole Hessler; Gisela Antony; Andreas Ziegler; Muna-Miriam Hoshi; Lilian Aly; Felix Luessi; Sergiu Groppa; Luisa Klotz; Sven G Meuth; Björn Tackenberg; Muriel Stoppe; Florian Then Bergh; Hayrettin Tumani; Tania Kümpfel; Martin Stangel; Christoph Heesen; Brigitte Wildemann; Friedemann Paul; Antonios Bayas; Clemens Warnke; Frank Weber; Ralf A Linker; Ulf Ziemann; Uwe K Zettl; Frauke Zipp; Heinz Wiendl; Bernhard Hemmer; Ralf Gold; Anke Salmen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-03-01

8.  Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue-Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers.

Authors:  Oliver Neuhaus; Wolfgang Köhler; Florian Then Bergh; Wolfgang Kristoferitsch; Jürgen Faiss; Thorsten Rosenkranz; Dirk Reske; Robert Patejdl; Hans-Peter Hartung; Uwe K Zettl
Journal:  Biomolecules       Date:  2021-03-07

9.  The Impact of Motor Disability and the Level of Fatigue on Adherence to Therapeutic Recommendations in Patients with Multiple Sclerosis Treated with Immunomodulation.

Authors:  Robert Ślusarz; Joanna Olkiewicz; Robert Bonek; Karolina Filipska; Monika Biercewicz; Adam Wiśniewski
Journal:  Int J Med Sci       Date:  2021-08-27       Impact factor: 3.738

10.  Assessment of factors associated with depression and anxiety among pwMS in Saudi Arabia.

Authors:  Safanah AlSaeed; Nuha M Alkhawajah; Mohsen Ayyash; Salman Aljarallah; Rola Alarieh; Amani Abu-Shaheen
Journal:  BMC Neurol       Date:  2022-03-25       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.